Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, parallel group, multicentre study of 12 weeks.

Trial Profile

Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, parallel group, multicentre study of 12 weeks.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ORM 12741 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms ALPO
  • Sponsors Orion; Orion Pharma

Most Recent Events

  • 26 Sep 2013 Results presented at the 21st World Congress of Neurology.
  • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
  • 20 Mar 2013 Results were presented at the American Academy of Neurology's Annual Meeting, according to an Orion Corporation media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top